RT Journal Article
SR Electronic
T1 A qualitative study of Benzodiazepine/Z-drug and Opioid co-use patterns and overdose risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.26.24311053
DO 10.1101/2024.07.26.24311053
A1 Family, Hannah E.
A1 Vojt, Gabriele
A1 Poulter, Hannah
A1 Bailey, Chris P.
A1 Sheikh, Ana Paula Abdala
A1 Cavallo, Damiana
A1 Karimi, Sara
A1 Booth, Nick
A1 Silva, Peter Da
A1 Aitken, Louise
A1 Stewart, Samantha
A1 Hickman, Matthew
A1 Henderson, Graeme
A1 Scott, Jennifer
A1 Kesten, Joanna M.
YR 2024
UL http://medrxiv.org/content/early/2024/08/30/2024.07.26.24311053.abstract
AB Background Co-use of benzodiazepines and/or ‘z-drugs’ along with opioids is linked to the rise in drug related deaths (DRD) in the UK. Understanding patterns of co-use could inform harm reduction strategies for reducing DRDs. This study explored how people co-use, including dosages, timings, methods of administration, use of other substances and desired effects sought.Methods Forty-eight semi-structured interviews across Glasgow in Scotland (n=28), Bristol (n=10) and Teesside (n=10) in England with individuals who co-use illicit and/or prescribed opioids and benzodiazepines/z-drugs were conducted. Eighteen interviews were co-facilitated with qualitatively trained local peer researchers. Interviews were analysed using the Framework method.Results Six co-use patterns were generated: (1) co-use to aid sleep or come down, (2) curated co-use, opioid agonist therapy (OAT) only (3) morning and evening benzodiazepine doses with opioids throughout the day (4) co-use binges (5) co-use throughout the day, (6) benzodiazepine use throughout the day plus OAT. Patterns one to three reflected more controlled co-use with a focus on self-medicating to give confidence, manage anxiety, promote sleep and come-down from cocaine/ketamine. Patterns four to six involved greater poly-drug use, and less controlled co-use with a focus on seeking euphoria (“warm glow”, “gouching out”) or oblivion (to escape untreated mental health conditions and trauma). Patterns two, three, five and six involved daily co-use. People switched between patterns depending on available resources (e.g. finances) or changes to prescriptions (opioids or benzodiazepines). Near-fatal overdoses were reported by participants across all co-use patterns. Patterns four to six were conceptualised as presenting greater overdose risk due to less controlled co-use and more extensive polydrug use.Conclusions The patterns identified provide opportunities for future harm reduction strategies, tailoring advice, updated prescribing guidance and policies, and the need for better access to mental health care, for people who co-use benzodiazepines and opioids to reduce DRDs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Medical Research Council grant number MR/W029162/1. JK and HF are partly funded by National Institute for Health Research Applied Research Collaboration West (NIHR ARC West) and NIHR HPRU in Behavioural Science and Evaluation. MH is funded by NIHR HPRU in Behavioural Science and Evaluation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the Faculty of Health Sciences Committee for Research Ethics, University of Bristol (ref 11906).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available on application at the University of Bristol data repository data.bris. Data access is restricted to bona fide researchers for ethically approved research and subject to approval by the University's Data Access Committee. https://data.bris.ac.uk/data/ UKUnited KingdomDRDDrug Related DeathOATOpioid Agonist TherapyOUDOpioid Use DisorderGABAAg-aminobutyric acid type A receptorsCLIP-Qcollaborative and intensive pragmatic qualitativeHATHeroin Assisted TreatmentHIVHuman immunodeficiency virus